MedImpact Hopes to Accelerate Adoption of Pharmacogenomics
With precision medicine an increasingly hot topic in health care, MedImpact is betting that a newly launched program — which reviews every drug prescribed to patients against their genetic profile — will simultaneously give the PBM a competitive edge and improve care. Experts tell AIS Health that such a program could usher in changes to the PBM industry if it proves successful and sparks a larger trend.
In a Feb. 26 press release, MedImpact describes its new program as the industry’s first “any drug, any time, any prescriber” approach to pharmacogenomics (PGx). “This highly personalized approach protects patients against hundreds of ineffective and harmful drugs based on their genetic profile. It will reduce ‘trial and error’ prescribing, reduce waste, lower the risk of adverse events, and improve member health,” the San Diego-based PBM said.